TheraRadar
Landscape → Oncology

Colorectal Cancer Clinical Trial Landscape

Data updated: May 20, 2026

2,540 clinical trials tracked since 2008

Colorectal cancer begins in the colon or rectum, sometimes called the large intestine, and can affect people of all ages, though it is most often diagnosed in older adults. Clinical trials are essential for developing new and improved treatments for this disease. Since 2008, 2,523 colorectal cancer trials have been registered, with 1,117 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 or Phase 2, with 391 and 731 trials respectively, while Phase 3 trials number 185 and Phase 4 trials total 21. This distribution suggests a strong focus on early-stage drug development and investigation of novel therapies. AbbVie leads industry sponsorship of active trials with 8, followed by AstraZeneca and Revolution Medicines, Inc., each with 7, Roche with 6, and Novartis with 5.

1122 active
/
2540 total (since 2008)
391
Phase 1 Active
997 total
737
Phase 2 Active
1577 total
185
Phase 3 Active
357 total
21
Phase 4 Active
64 total

Top Industry Sponsors

Sorted by active Active Done Failed
AbbVie 8 3 3
AstraZeneca 7 4 2
Revolution Medicines, Inc. 7 0 0
Roche 6 29 7
Novartis 5 6 8

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07113275 RECRUITING
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Tao Zhang n=444
NCT02997228 ACTIVE NOT RECRUITING
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI) n=120
NCT07152821 RECRUITING
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Canadian Cancer Trials Group n=834
NCT06123156 RECRUITING
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
University Hospital, Rouen n=188
NCT06205485 RECRUITING
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Canadian Cancer Trials Group n=250

+ 352 more Phase 3 trials — see full database below

Colorectal Cancer — Trials Started by Year (last 10 years)

2016
98
2017
112
2018
144
2019
130
2020
119
2021
135
2022
147
2023
193
2024
244
2025
280
2026
164

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AbbVie
14
AstraZeneca
13
Revolution Medicines, Inc.
7
Roche
42
Novartis
19
Chongqing Precision Biotech Co., Ltd
5
Pfizer
23
Bristol-Myers Squibb
14
Shanghai Henlius Biotech
6
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
5

Active Trials by Phase

Phase 1
391
Phase 2
737
Phase 3
185
Phase 4
21

Enrollment Size Distribution

1-50
1,119
51-200
871
201-500
288
501-1k
109
1k+
39

All Industry Sponsors

Sorted by active Active Done Failed
AbbVie 8 3 3
AstraZeneca 7 4 2
Revolution Medicines, Inc. 7 0 0
Roche 6 29 7
Novartis 5 6 8
Chongqing Precision Biotech Co., Ltd 5 0 0
Pfizer 4 10 9
Bristol-Myers Squibb 4 8 2
Shanghai Henlius Biotech 4 1 1
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 4 0 1
Akeso 4 0 0
IDEAYA Biosciences 4 0 0
Exelixis 4 0 0
Qilu Pharmaceutical Co., Ltd. 4 0 0
Eli Lilly 3 10 3
NCT07585279 NOT YET RECRUITING
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Hebei Medical University Fourth Hospital n=408
NCT07113275 RECRUITING
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Tao Zhang n=444
NCT02997228 ACTIVE NOT RECRUITING
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI) n=120
NCT07152821 RECRUITING
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Canadian Cancer Trials Group n=834
NCT06123156 RECRUITING
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
University Hospital, Rouen n=188
NCT06205485 RECRUITING
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Canadian Cancer Trials Group n=250
NCT06758830 RECRUITING
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos n=400
NCT05673148 RECRUITING
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Alliance for Clinical Trials in Oncology n=364
NCT07549412 RECRUITING
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
EMD Serono Research & Development Institute, Inc. n=1,020
NCT07284849 RECRUITING
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation n=700
NCT06936774 RECRUITING
Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
University Hospital, Basel, Switzerland n=140
NCT05174169 RECRUITING
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NRG Oncology n=1,912
NCT07221357 RECRUITING
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb n=990
NCT05863195 RECRUITING
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
ECOG-ACRIN Cancer Research Group n=408
NCT07219238 RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare n=175
NCT07228832 RECRUITING
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Summit Therapeutics n=600
NCT07454720 RECRUITING
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=165
NCT02912559 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI) n=712
NCT03803553 RECRUITING
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital n=400
NCT01558921 ACTIVE NOT RECRUITING
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
University Medical Center Groningen n=920
NCT07528209 RECRUITING
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University n=556
NCT07558083 RECRUITING
FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
University Hospital, Antwerp n=150
NCT06850090 RECRUITING
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Shandong Cancer Hospital and Institute n=210
NCT04793958 ACTIVE NOT RECRUITING
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics Inc. n=461
NCT06252649 RECRUITING
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Amgen n=450
NCT07551479 NOT YET RECRUITING
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
Fudan University n=612
NCT07412613 RECRUITING
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso n=386
NCT05652894 ACTIVE NOT RECRUITING
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD n=190
NCT06280495 RECRUITING
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University n=156
NCT07537998 RECRUITING
Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.
Pei-Rong Ding n=160
NCT07525206 NOT YET RECRUITING
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie n=700
NCT07520578 NOT YET RECRUITING
EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO)
University Hospital, Caen n=2,000
NCT07509398 NOT YET RECRUITING
FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer
Shanghai 10th People's Hospital n=220
NCT07505472 RECRUITING
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
The First Hospital of Jilin University n=212
NCT07018869 RECRUITING
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
SWOG Cancer Research Network n=1,057
NCT02758951 ACTIVE NOT RECRUITING
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
Koen Rovers n=358
NCT06497985 RECRUITING
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd. n=430
NCT07483684 NOT YET RECRUITING
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. n=142
NCT05179889 RECRUITING
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Chungnam National University Hospital n=308
NCT07472868 NOT YET RECRUITING
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
J. W. A. Burger n=394
NCT02647099 ACTIVE NOT RECRUITING
Adjuvant Low Dose Aspirin in Colorectal Cancer
Anna Martling n=626
NCT01918527 ACTIVE NOT RECRUITING
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Vejle Hospital n=250
NCT04230187 RECRUITING
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
Yanhong Deng n=528
NCT04215731 RECRUITING
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Yanhong Deng n=582
NCT04928807 ACTIVE NOT RECRUITING
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=231
NCT04428905 ACTIVE NOT RECRUITING
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center n=403
NCT06446557 NOT YET RECRUITING
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
University Hospital, Rouen n=408
NCT02945033 RECRUITING
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
University Hospital, Rouen n=264
NCT05171660 ACTIVE NOT RECRUITING
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University n=446
NCT03051464 RECRUITING
No Surgery Trial / Two Dose-escalation Strategies
Sir Mortimer B. Davis - Jewish General Hospital n=131
NCT01460589 ACTIVE NOT RECRUITING
Early Commencement of Adjuvant Chemotherapy for Colon Cancer
Kyungpook National University Hospital n=303
NCT03426904 ACTIVE NOT RECRUITING
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Kyungpook National University Hospital n=708
NCT06107920 RECRUITING
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
University Hospital, Rouen n=232
NCT04749108 RECRUITING
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Institut du Cancer de Montpellier - Val d'Aurelle n=1,075
NCT07389265 RECRUITING
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
University of Campania Luigi Vanvitelli n=480
NCT06501482 RECRUITING
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Assistance Publique - Hôpitaux de Paris n=254
NCT06563388 RECRUITING
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Roswell Park Cancer Institute n=800
NCT07384377 NOT YET RECRUITING
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc. n=123
NCT02448173 NOT YET RECRUITING
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Vaccinogen Inc n=550
NCT04495088 RECRUITING
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Ralf Hofheinz n=550
NCT04854668 ACTIVE NOT RECRUITING
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=748
NCT07372300 RECRUITING
Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer
Shih-Kai Hung n=126
NCT05710406 ACTIVE NOT RECRUITING
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Alliance for Clinical Trials in Oncology n=1
NCT04137107 ACTIVE NOT RECRUITING
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
Alliance for Clinical Trials in Oncology n=220
NCT07362836 NOT YET RECRUITING
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
Fudan University n=224
NCT07361003 RECRUITING
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. n=464
NCT03875781 RECRUITING
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
Assistance Publique - Hôpitaux de Paris n=540
NCT07340567 NOT YET RECRUITING
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
UNICANCER n=2,450
NCT06312982 RECRUITING
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
Beijing Friendship Hospital n=375
NCT07321847 NOT YET RECRUITING
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
Immunophotonics, Inc. n=717
NCT07309289 RECRUITING
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital n=144
NCT06791512 RECRUITING
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Jun Huang n=166
NCT03869892 ACTIVE NOT RECRUITING
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Institut de Recherches Internationales Servier n=856
NCT06686576 RECRUITING
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Qilu Pharmaceutical Co., Ltd. n=363
NCT07284394 NOT YET RECRUITING
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
UNICANCER n=272
NCT05008809 RECRUITING
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Dominik Paul Modest n=507
NCT07277842 NOT YET RECRUITING
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University n=382
NCT07272772 RECRUITING
Colon Cancer Diagnosis With FAPI-PET Imaging
Turku University Hospital n=100
NCT07271355 NOT YET RECRUITING
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center n=129
NCT06733038 RECRUITING
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Gruppo Oncologico del Nord-Ovest n=238
NCT06783491 NOT YET RECRUITING
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer
Maimónides Biomedical Research Institute of Córdoba n=1,083
NCT03829462 ACTIVE NOT RECRUITING
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Institut du Cancer de Montpellier - Val d'Aurelle n=377
NCT06940947 RECRUITING
Endoscopic Therapy Or Surgery for Early Colon Cancer
Norwegian Department of Health and Social Affairs n=434
NCT05945901 ACTIVE NOT RECRUITING
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd. n=669
NCT05425940 ACTIVE NOT RECRUITING
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Exelixis n=901
NCT04008030 ACTIVE NOT RECRUITING
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Bristol-Myers Squibb n=839
NCT04776655 RECRUITING
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
Azienda USL Reggio Emilia - IRCCS n=280
NCT07188025 NOT YET RECRUITING
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
Erasmus Medical Center n=103
NCT06008119 RECRUITING
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc. n=165
NCT06490536 RECRUITING
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology n=700
NCT06614192 RECRUITING
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie n=460
NCT07134218 NOT YET RECRUITING
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
Changhai Hospital n=180
NCT07134205 NOT YET RECRUITING
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc. n=252
NCT07132463 NOT YET RECRUITING
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
Fudan University n=154
NCT06958419 RECRUITING
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
Sixth Affiliated Hospital, Sun Yat-sen University n=286
NCT06958432 RECRUITING
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University n=430
NCT03326791 ACTIVE NOT RECRUITING
Aspirin in Colorectal Cancer Liver Metastases
Oslo University Hospital n=466
NCT06839092 NOT YET RECRUITING
Prophylactic PIPAC in Patients With High-risk Colorectal Cancer
Jeremy Meyer n=160
NCT06441565 RECRUITING
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University n=84
NCT07074353 NOT YET RECRUITING
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Zhejiang Cancer Hospital n=360
NCT03828227 ACTIVE NOT RECRUITING
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.
GERCOR - Multidisciplinary Oncology Cooperative Group n=49
NCT07070622 RECRUITING
Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)
West China Hospital n=186
NCT06199973 ACTIVE NOT RECRUITING
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=130
NCT04922853 ACTIVE NOT RECRUITING
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
West China Hospital n=554
NCT06507371 RECRUITING
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Sir Run Run Shaw Hospital n=170
NCT07025239 NOT YET RECRUITING
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd. n=430
NCT07020247 RECRUITING
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
West China Hospital n=184
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT07004413 NOT YET RECRUITING
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
Charite University, Berlin, Germany n=267
NCT04861558 RECRUITING
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
Uppsala University n=213
NCT06992648 RECRUITING
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University n=302
NCT06968221 RECRUITING
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Shanghai Cingularbio Co. Ltd n=172
NCT06332274 RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Gustave Roussy, Cancer Campus, Grand Paris n=717
NCT06794086 RECRUITING
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Jun Huang n=24
NCT04068103 ACTIVE NOT RECRUITING
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology n=635
NCT06959693 NOT YET RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Sun Yat-sen University n=590
NCT06555003 RECRUITING
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
Tehran University of Medical Sciences n=116
NCT03428477 ACTIVE NOT RECRUITING
EPA for Metastasis Trial 2
Mark A Hull, PhD FRCP n=418
NCT05646511 RECRUITING
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
National Cancer Center Hospital East n=608
NCT06293625 RECRUITING
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
Centre Hospitalier Universitaire Dijon n=150
NCT06899477 NOT YET RECRUITING
Pre-Operative Treatment in REseCTable COlon CanceR
Dominik Paul Modest n=714
NCT02572141 ACTIVE NOT RECRUITING
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
Sun Yat-sen University n=738
NCT06832917 NOT YET RECRUITING
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
Wan He n=238
NCT06845306 NOT YET RECRUITING
The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery
Vadim Kuznetsov n=1,268
NCT05709249 RECRUITING
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Jiangsu Famous Medical Technology Co., Ltd. n=730
NCT02843191 ACTIVE NOT RECRUITING
Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy
Kyung Hee University Hospital at Gangdong n=358
NCT05462613 RECRUITING
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon n=446
NCT04687631 RECRUITING
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Fudan University n=508
NCT06709144 ACTIVE NOT RECRUITING
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
Haixing Ju, MD n=896
NCT05534087 RECRUITING
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Seoul National University Hospital n=236
NCT06520683 RECRUITING
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
Sun Yat-sen University n=180
NCT04516681 RECRUITING
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Fudan University n=400
NCT03635021 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) n=419
NCT04547166 RECRUITING
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Shanghai Henlius Biotech n=568
NCT06646809 RECRUITING
Reducing Inflammatory Syndrome in Surgery - Colorectal (RISIS-CR) Trial
National University Hospital, Singapore n=80
NCT06275958 RECRUITING
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Leiden University Medical Center n=587
NCT06642844 NOT YET RECRUITING
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
University Hospital, Tours n=244
NCT06616259 NOT YET RECRUITING
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
Meng Qiu n=452
NCT06609551 RECRUITING
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
Zhejiang Cancer Hospital n=312
NCT05168839 RECRUITING
Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
Centre Hospitalier Universitaire de Besancon n=1,010
NCT04246684 ACTIVE NOT RECRUITING
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
Prof. Dr. med. Claus Rödel n=702
NCT06185556 RECRUITING
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Amsterdam UMC, location VUmc n=78
NCT06566755 RECRUITING
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Caigang Liu n=30
NCT03879109 ACTIVE NOT RECRUITING
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer
University Hospital, Bordeaux n=58
NCT05939687 RECRUITING
Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection
Blokhin's Russian Cancer Research Center n=142
NCT06509126 RECRUITING
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
National Cancer Institute, Naples n=500
NCT06243393 RECRUITING
Sacituzumab Govitecan in Metastatic Colorectal Cancer
University Hospital Heidelberg n=80
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06450574 NOT YET RECRUITING
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)
Corporacion Parc Tauli n=106
NCT06443671 NOT YET RECRUITING
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
Peking University Cancer Hospital & Institute n=132
NCT05954078 RECRUITING
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Fudan University n=340
NCT06343116 NOT YET RECRUITING
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Biotech Pharmaceutical Co., Ltd. n=420
NCT03464305 ACTIVE NOT RECRUITING
ASPIRIN Trial Belgium
University Hospital, Antwerp n=148
NCT02301286 ACTIVE NOT RECRUITING
A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Leiden University n=770
NCT03413254 ACTIVE NOT RECRUITING
Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=389
NCT06229041 RECRUITING
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
Peking University Cancer Hospital & Institute n=472
NCT06134388 RECRUITING
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Tanta University n=50
NCT06097416 NOT YET RECRUITING
Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer
St. James's Hospital, Ireland n=100
NCT05984485 RECRUITING
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Sun Yat-sen University n=766
NCT05948072 NOT YET RECRUITING
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
Fudan University n=250
NCT05797467 RECRUITING
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Sixth Affiliated Hospital, Sun Yat-sen University n=366
NCT05861505 RECRUITING
COLLISION RELAPSE Trial
Amsterdam UMC, location VUmc n=360
NCT05794971 RECRUITING
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
Sun Yat-sen University n=126
NCT05752136 RECRUITING
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Sir Run Run Shaw Hospital n=108
NCT04087421 RECRUITING
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
University of Aarhus n=114
NCT05815082 RECRUITING
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University n=490
NCT05797077 RECRUITING
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Sixth Affiliated Hospital, Sun Yat-sen University n=346
NCT05768503 RECRUITING
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Sun Yat-sen University n=176
NCT05699746 NOT YET RECRUITING
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Zhejiang University n=38
NCT05236972 RECRUITING
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University n=323
NCT05427669 NOT YET RECRUITING
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
Yanhong Deng n=340
NCT04389086 RECRUITING
Induction Chemotherapy for Locally Recurrent Rectal Cancer
Catharina Ziekenhuis Eindhoven n=364
NCT05201430 RECRUITING
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
Fudan University n=300
NCT05194878 RECRUITING
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Sun Yat-sen University n=840
NCT04120701 RECRUITING
CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
Centre Hospitalier Universitaire Dijon n=1,980
NCT05086614 RECRUITING
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Fudan University n=2,500
NCT04089631 RECRUITING
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
Technische Universität Dresden n=4,812
NCT04288999 RECRUITING
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
National Cancer Center Hospital East n=110
NCT03975049 NOT YET RECRUITING
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University n=933
NCT03925662 RECRUITING
Mebendazole as Adjuvant Treatment for Colon Cancer
Sherief Abd-Elsalam n=40
NCT03671252 RECRUITING
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
Sun Yat-sen University n=776
NCT00883792 ACTIVE NOT RECRUITING
The Northern-European Initiative on Colorectal Cancer
Oslo University Hospital n=95,000
NCT03125980 RECRUITING
Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
Fudan University n=1,370
NCT07595276 NOT YET RECRUITING
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Taizhou Mabtech Pharmaceutical Co.,Ltd n=608
NCT03426371 TERMINATED
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=52
NCT04835142 COMPLETED
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=688
NCT05198934 COMPLETED
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Amgen n=160
NCT02584985 COMPLETED
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Institut Paoli-Calmettes n=226
NCT01226394 COMPLETED
Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients
Gustave Roussy, Cancer Campus, Grand Paris n=150
NCT02956876 COMPLETED
Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer
University Hospital, Rouen n=207
NCT07320950 COMPLETED
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University n=333
NCT05215379 COMPLETED
Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
Changhai Hospital n=201
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT05600309 COMPLETED
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC n=94
NCT02967289 COMPLETED
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
UNICANCER n=792
NCT01999634 COMPLETED
Monitoring by Microdialysis of Postoperative Complications After Proctectomy
Centre Hospitalier Universitaire, Amiens n=21
NCT01727388 COMPLETED
Informativeness to Digital Rectal Examination
Centre Hospitalier Universitaire, Amiens n=320
NCT05064059 COMPLETED
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Merck Sharp & Dohme LLC n=441
NCT02605265 COMPLETED
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
Fudan University n=356
NCT04941300 COMPLETED
ColoRectal Cancer Screening for Southern California Community Health Centers
University of California, San Diego n=55,999
NCT05625932 COMPLETED
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Galician Research Group on Digestive Tumors n=232
NCT06728982 COMPLETED
Impact Of Metformin In Rectal Cancer Patients
Minia University n=85
NCT03206151 COMPLETED
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd n=520
NCT04856787 TERMINATED
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=62
NCT02467582 TERMINATED
Adjuvant Aspirin Treatment for Colon Cancer Patients
Swiss Cancer Institute n=1,040
NCT02934529 COMPLETED
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
Ludwig-Maximilians - University of Munich n=673
NCT04322539 COMPLETED
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Hutchison Medipharma Limited n=691
NCT04316013 TERMINATED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Peter MacCallum Cancer Centre, Australia n=254
NCT02162563 COMPLETED
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
Dutch Colorectal Cancer Group n=530
NCT03511963 COMPLETED
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Shanghai Henlius Biotech n=677
NCT01167725 TERMINATED
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology n=340
NCT04607668 TERMINATED
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
G1 Therapeutics, Inc. n=326
NCT04456699 COMPLETED
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Merck Sharp & Dohme LLC n=335
NCT02494973 COMPLETED
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases
Gustave Roussy, Cancer Campus, Grand Paris n=104
NCT02563002 COMPLETED
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Merck Sharp & Dohme LLC n=307
NCT04737187 COMPLETED
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Taiho Oncology, Inc. n=492
NCT04488159 WITHDRAWN
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
Johannes Laengle, MD, PhD
NCT01607957 COMPLETED
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Taiho Oncology, Inc. n=800
NCT05223673 TERMINATED
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
Institut de Recherches Internationales Servier n=7
NCT02514278 COMPLETED
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
University Hospital, Bordeaux n=218
NCT03520946 COMPLETED
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=430
NCT03306394 COMPLETED
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
Institut de Recherches Internationales Servier n=907
NCT01345175 COMPLETED
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Memorial Sloan Kettering Cancer Center n=69
NCT05021263 COMPLETED
Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?
Thomas Jefferson University n=90
NCT03781154 COMPLETED
Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
University of Colorado, Denver n=31
NCT05726097 COMPLETED
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
Region Skane n=147
NCT05921942 COMPLETED
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer
Ain Shams University n=70
NCT03500874 TERMINATED
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
Sun Yat-sen University n=92
NCT03491540 COMPLETED
Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery
Assistance Publique - Hôpitaux de Paris n=414
NCT02928224 COMPLETED
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Pfizer n=702
NCT02519140 WITHDRAWN
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Antonios Likourezos
NCT03414983 COMPLETED
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
Bristol-Myers Squibb n=196
NCT02753127 COMPLETED
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Sumitomo Pharma America, Inc. n=1,253
NCT02394795 COMPLETED
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Takeda n=823
NCT03750786 COMPLETED
A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Isofol Medical AB n=490
NCT02551237 COMPLETED
Neoadjuvant Treatment for Advanced Rectal Carcinoma
UNICANCER n=103
NCT01606098 COMPLETED
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
Dutch Colorectal Cancer Group n=206
NCT01830621 COMPLETED
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
NCIC Clinical Trials Group n=282
NCT01011478 TERMINATED
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
NSABP Foundation Inc n=406
NCT00640471 COMPLETED
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
NCIC Clinical Trials Group n=750
NCT01718873 COMPLETED
Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
National Cancer Institute, Naples n=230
NCT03742596 WITHDRAWN
Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients
King Hussein Cancer Center
NCT03678428 TERMINATED
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
Sun Yat-sen University n=92
NCT03231722 COMPLETED
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
Gruppo Oncologico del Nord-Ovest n=435
NCT02870582 COMPLETED
Donafenib for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=536
NCT01099449 COMPLETED
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Alliance for Clinical Trials in Oncology n=362
NCT03827044 TERMINATED
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
Royal Marsden NHS Foundation Trust n=30
NCT01001377 COMPLETED
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen n=1,010
NCT03462563 TERMINATED
Prospective, Multicenter, Randomized Controlled Study to Evaluate the Effect of INTERCEED™
Ethicon, Inc. n=175
NCT01648894 COMPLETED
Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer
Assistance Publique - Hôpitaux de Paris n=265
NCT03970694 TERMINATED
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer
Sun Yat-sen University n=49
NCT03475680 TERMINATED
Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery
Assistance Publique - Hôpitaux de Paris n=193
NCT02588248 TERMINATED
L-Menthol Injection as a Novel Technique During Colonoscopy
University Hospitals Cleveland Medical Center n=82
NCT02664077 TERMINATED
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
NSABP Foundation Inc n=34
NCT04034355 TERMINATED
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
Egetis Therapeutics n=301
NCT03654729 TERMINATED
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
Egetis Therapeutics n=291
NCT00995202 COMPLETED
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer
Federation Francophone de Cancerologie Digestive n=1,997
NCT01308190 COMPLETED
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer
Corporacion Parc Tauli n=173
NCT01927497 COMPLETED
Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=104
NCT02909478 COMPLETED
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
Sun Yat-sen University n=315
NCT01767857 TERMINATED
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Janssen Research & Development, LLC n=643
NCT03158610 TERMINATED
Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
Ruijin Hospital n=20
NCT02195232 COMPLETED
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Jeffrey Zwicker, MD n=64
NCT02138422 COMPLETED
A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
Janssen Research & Development, LLC n=276
NCT01318161 TERMINATED
Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery
Örebro University, Sweden n=221
NCT03031444 COMPLETED
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
Peking University Cancer Hospital & Institute n=135
NCT03288987 COMPLETED
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
AryoGen Pharmed Co. n=126
NCT01224392 COMPLETED
Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer
Universitair Ziekenhuis Brussel n=156
NCT02390947 COMPLETED
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Jiangsu HengRui Medicine Co., Ltd. n=543
NCT03556956 COMPLETED
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
AB Science n=219
NCT01955837 COMPLETED
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
Taiho Pharmaceutical Co., Ltd. n=406
NCT03565354 COMPLETED
Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients
Prince of Wales Hospital, Shatin, Hong Kong n=40
NCT02453490 TERMINATED
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
Zhejiang University n=360
NCT03300609 TERMINATED
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
University of Southern California n=4
NCT00726622 COMPLETED
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Alliance for Clinical Trials in Oncology n=486
NCT04342676 COMPLETED
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Mansoura University n=433
NCT00952029 COMPLETED
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive n=492
NCT02314819 COMPLETED
A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)
Hutchison Medipharma Limited n=416
NCT01228734 COMPLETED
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
Merck KGaA, Darmstadt, Germany n=553
NCT01741038 WITHDRAWN
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
Mirror Biologics, Inc.
NCT00706121 COMPLETED
S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
SWOG Cancer Research Network n=8,094
NCT01902823 TERMINATED
Effect of Cancer Nurse Navigators on Patient Outcomes
University of Wisconsin, Madison n=16
NCT02788279 COMPLETED
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Hoffmann-La Roche n=363
NCT01721954 COMPLETED
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Sirtex Medical n=209
NCT02251977 COMPLETED
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
Yuhong Li n=196
NCT01183780 COMPLETED
A Study in Second Line Metastatic Colorectal Cancer
Eli Lilly and Company n=1,072
NCT02332499 COMPLETED
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=419
NCT01640405 COMPLETED
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) n=350
NCT01550055 COMPLETED
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
Shanghai Zhangjiang Biotechnology Limited Company n=512
NCT03248661 COMPLETED
Assessing Repeat Fit Testing for CRC
Richard Crosby n=220
NCT02605044 TERMINATED
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
AB Science n=123
NCT03717038 WITHDRAWN
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
NCT01842971 TERMINATED
ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis
Centre Hospitalier Universitaire, Amiens n=3
NCT00749450 COMPLETED
Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer
Cancer Research UK, Glasgow n=6,088
NCT02127645 COMPLETED
Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer
European Association for Endoscopic Surgery n=25
NCT02273141 COMPLETED
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.
Norgine n=515
NCT02273167 COMPLETED
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
Norgine n=849
NCT02706184 COMPLETED
E. Coli Nissle in Oncology
University of Hohenheim n=20
NCT02254486 COMPLETED
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
Norgine n=621
NCT02284139 COMPLETED
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
Dong-A University Hospital n=90
NCT01571284 COMPLETED
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Sanofi n=781
NCT01918852 COMPLETED
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Dutch Colorectal Cancer Group n=161
NCT02163187 TERMINATED
Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Memorial Sloan Kettering Cancer Center n=4
NCT00911170 COMPLETED
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen n=847
NCT01279681 TERMINATED
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology n=32
NCT01694966 COMPLETED
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Cosmo Technologies Ltd n=1,249
NCT01309126 TERMINATED
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
HiberCell, Inc. n=217
NCT00687830 COMPLETED
Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
Cleveland Clinic Florida n=136
NCT01646554 WITHDRAWN
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
European Organisation for Research and Treatment of Cancer - EORTC
NCT02060669 TERMINATED
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
Samsung Medical Center n=10
NCT01523431 COMPLETED
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences n=583
NCT01412957 COMPLETED
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Amgen n=377
NCT01786694 COMPLETED
Feasibility of Microdialysis by Laparoscopy
Centre Hospitalier Universitaire, Amiens n=11
NCT01670721 COMPLETED
Colorectal Cancer Metastatic
Sanofi n=175
NCT01338558 WITHDRAWN
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
Hoffmann-La Roche
NCT01661270 COMPLETED
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Sanofi n=332
NCT00766155 COMPLETED
Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC n=1,094
NCT02266849 TERMINATED
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
Odense University Hospital n=12
NCT01372007 COMPLETED
Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma
University Hospital, Ghent n=24
NCT00769405 COMPLETED
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER n=264
NCT00660894 COMPLETED
Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=1,535
NCT02813278 COMPLETED
Simo Decoction and Acupuncture on POI in Colorectal Cancer
Guangxi Medical University n=600
NCT01233544 TERMINATED
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
University of Aarhus n=300
NCT02548403 COMPLETED
Effect of Simethicone on Bowel Preparation for Colonoscopy
Korea University Anam Hospital n=260
NCT01483443 COMPLETED
Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Cancer Patients
Gachon University Gil Medical Center n=140
NCT01269567 COMPLETED
Drainage After Rectal Excision for Rectal Cancer
University Hospital, Bordeaux n=494
NCT01030042 COMPLETED
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente n=110
NCT01103323 COMPLETED
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Bayer n=760
NCT00735241 WITHDRAWN
FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
Sirtex Medical
NCT01103479 COMPLETED
Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening
Northwestern University n=569
NCT02419677 COMPLETED
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases
The First People's Hospital of Changzhou n=60
NCT01229813 COMPLETED
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Lund University Hospital n=233
NCT00720512 TERMINATED
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
Gruppo Oncologico del Nord-Ovest n=184
NCT00719797 COMPLETED
Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest n=509
NCT02250196 COMPLETED
A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
Korea University Anam Hospital n=200
NCT00623805 COMPLETED
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche n=123
NCT01410955 COMPLETED
Prevention of Irinotecan Induced Diarrhea by Probiotics
Monsea Ltd. n=46
NCT00756548 COMPLETED
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Braintree Laboratories n=386
NCT00975897 COMPLETED
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Medical Research Council n=3,240
NCT01506687 COMPLETED
Increasing Colorectal Cancer Screening Uptake With a Patient Navigator
Cancer Care Ontario n=750
NCT01086618 COMPLETED
Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
University College London Hospitals n=500
NCT00756977 COMPLETED
BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Braintree Laboratories n=394
NCT01097018 COMPLETED
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
AEterna Zentaris n=468
NCT00677443 COMPLETED
Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
Samsung Medical Center n=344
NCT01872104 SUSPENDED
Safety and Efficiency of Photodynamic Therapy for Rectal Cancer
li xiong n=100
NCT01189227 TERMINATED
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
NSABP Foundation Inc n=9
NCT01341366 COMPLETED
Fast-track Perioperative Program for Laparoscopic Colorectal Surgery
Chinese University of Hong Kong n=128
NCT01324284 COMPLETED
Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy
Asian Institute of Gastroenterology, India n=442
NCT01786538 WITHDRAWN
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Asan Medical Center
NCT01778192 COMPLETED
A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate
Korea University Anam Hospital n=200
NCT00981110 COMPLETED
Standard Versus Advanced Antimicrobial Dressing Containing Ionic Silver Following Colorectal Cancer Surgery
European Institute of Oncology n=120
NCT01072851 COMPLETED
Tools for Improving Colorectal Cancer Screening Rates: Multimedia Versus Print
Trinity Health Of New England n=920
NCT01251666 COMPLETED
Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening
University Hospital, Caen n=19,797
NCT01370928 COMPLETED
Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial
Sorlandet Hospital HF n=190
NCT00911391 COMPLETED
Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy
University of Auckland, New Zealand n=85
NCT01150045 COMPLETED
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology n=2,527

Full Colorectal Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only